This NDC is on FDA's drug shortage list (posted Jul 26, 2023)
Product Information
RELEXXII ER 63 MG TABLET is a brand product labeled by Vertical Pharmaceuticals, LLC, priced at $21.3526 per EA under NDC 68025008930. Its NADAC has been published 33 times since Feb 18, 2026.
FDA first approved this application on Jun 23, 2022.
The High Outlier badge above means this manufacturer's average price in the methylphenidate hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
63 mg/1
Manufacturer
Vertical Pharmaceuticals, LLCNDC
68025008930
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA216117FDA Approved
6/23/2022
On Market Since
6/23/2022
Pharmacological Classes
Price Statistics
The NADAC for RELEXXII ER 63 MG TABLET has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $21.3526 per EA |
|---|---|
| All-time high | $21.4709 (May 13, 2026) |
| All-time low | $21.2892 (May 20, 2026) |
| 52-week high | $21.4709 |
| 52-week low | $21.2892 |
| Median price | $21.3700 |
| Average price | $21.3823 |
| Largest weekly change | -0.8% (May 20, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the methylphenidate hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vertical Pharmaceuticals, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
methylphenidate hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RELEXXII ER 63 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RELEXXII ER 63 MG TABLET, manufactured by Vertical Pharmaceuticals, LLC, is $21.3526 per EA (NDC 68025008930), effective Sep 30, 2026.
How has the price of RELEXXII ER 63 MG TABLET changed over time?
Over the history we have for it, the NADAC for RELEXXII ER 63 MG TABLET has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for RELEXXII ER 63 MG TABLET?
Since Feb 18, 2026, the NADAC for RELEXXII ER 63 MG TABLET has ranged from a low of $21.2892 (May 20, 2026) to a high of $21.4709 (May 13, 2026), with a median of $21.3700 per EA.
Are there cheaper alternatives to RELEXXII ER 63 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of RELEXXII ER 63 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RELEXXII ER 63 MG TABLET?
RELEXXII ER 63 MG TABLET (NDC 68025008930) is labeled by Vertical Pharmaceuticals, LLC, and CMS classifies it as a brand product.
Is RELEXXII ER 63 MG TABLET in shortage?
Yes — NDC 68025008930 is currently listed in FDA's drug shortage database (posted Jul 26, 2023).